Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01296477 · ClinicalTrials.gov registry record

To Evaluate the Use of ASTHMA IQ in a Primary Care Setting

A clinical trial, sponsored by American Academy of Family Physicians.

Completed
Registry status
375
Enrollment target

NCT01296477: Completed study, sponsored by American Academy of Family Physicians.

NCT01296477 is a clinical trial that has completed, run by American Academy of Family Physicians. The registered enrollment target is 375 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01296477 has completed, sponsored by American Academy of Family Physicians.

COMPLETED
Registry status
375 participants
Enrollment target

Study Summary

There is a mounting body of evidence suggesting that there is a large disparity between the development and the actual implementation of guideline-driven asthma care in primary and specialty care practices. To address this disparity, the American Academy of Allergy, Asthma \& Immunology (AAAAI) developed a unique, comprehensive and easy-to-use Web-based tool for clinicians who treat asthma patients called "Asthma Specialist Tool to Help Manage Asthma and Improve Quality" (Asthma-IQ). This study will examine whether the use of the Asthma IQ primary care tool will improve asthma care and asthma outcomes using a randomized trial of the Asthma IQ system versus usual asthma care in the primary care setting over 1 year. At the end of 1 year, all patients will be managed using the Asthma-IQ tool for an additional year to determine if the patients managed by usual care in the first year improve when managed in conjunction with Asthma-IQ. The primary endpoint to determine if the use of the Asthma IQ tool will improve asthma patient outcomes is quarterly assessments of Asthma Control Test (ACT) scores via automated / electronic patient survey. The secondary endpoint is asthma exacerbations and there are a number of exploratory endpoints to further define the clinical utility of the primary care version of Asthma-IQ. This study will involve recruiting approximately 20 family medicine offices with approximately 20 patients each, to conduct this randomized, multiple time point intervention trial. The necessary total recruited patient sample size is 200 per group. The results of this study will help determine the utility of Web-based tools to help manage chronic diseases such as asthma.

Trial Details

FieldValue
Enrollment Target 375 participants
Start Date 2010-12
Est. Completion 2015-09

What the finished NCT01296477 record still lists

NCT01296477 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT01296477 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01296477 about?

NCT01296477 is a clinical study titled "To Evaluate the Use of ASTHMA IQ in a Primary Care Setting". There is a mounting body of evidence suggesting that there is a large disparity between the development and the actual implementation of guideline-driven asthma care in primary and specialty care practices. To address this disparity, the American Academy of Allergy, Asthma \& Immunology (AAAAI) deve...

What is the current status of trial NCT01296477?

This trial is currently completed. The enrollment target is 375 participants. The study started on 2010-12. Estimated completion is 2015-09.

Who is sponsoring clinical trial NCT01296477?

This trial is sponsored by American Academy of Family Physicians, which has 6 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03686124 · 375 participants · Phase 1

    ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

  • NCT04059172 · 375 participants · Early Phase 1

    Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management

  • NCT04134923 · 375 participants

    Imaging Biomarkers in Preclinical and Symptomatic AD

  • NCT04569747 · 375 participants · Phase 2

    A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01296477, the US trial registry maintained by the National Library of Medicine. NCT01296477 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.